Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: A multicentric phase II study

C. Aschele, A. Guglielmi, G. L. Frassineti, C. Milandri, D. Amadori, R. Labianca, M. Vinci, L. Tixi, C. Caroti, E. Ciferri, E. Verdi, R. Rosso, A. Sobrero

Research output: Contribution to journalArticle

Abstract

We have recently reported high clinical activity against advanced colorectal cancer of a regimen-alternating bolus FUra, modulated by methotrexate (MTX), and continuous infusion FUra, modulated by 6-s-leucovorin (6-s-LV). Considering the low toxicity of the bolus part of this regimen and our recent in vitro finding of a strong synergism between bolus FUra and natural-β-IFN (n-β-IFN), this cytokine was incorporated in the bolus part of our treatment programme. Fifty-six patients with untreated, advanced, measurable colorectal cancer were treated with two biweekly cycles of FUra bolus (600 mg m-2), modulated by MTX (24 h earlier, 200 mg m-2), and n-β-IFN (3 x 106 IU i.m. every 12 h, starting at the time of FUra administration for four doses), alternating with a 3-week continuous infusion of FUra (200 mg m-2 daily), modulated by 6-s-LV (20 mg m-2 weekly bolus). After a 1-week rest, the whole cycle (8 weeks) was repeated if indicated. A total of 5 complete and 17 partial responses were obtained (response rate, 41%; 95% confidence limits, 28-55%) in 54 assessable patients. After a median follow-up time of 36 months, five patients are still alive. Overall, the median time to treatment failure was 6.4 months. The median duration of survival was 15.0 months. There was one treatment-related death after a course of MTX → bolus FUra/n-β-IFN and grade III-IV toxicity occurred in 18% of the patients. As the addition of n-β-IFN results in high toxicity, whereas the efficacy seems to be similar to that of the same regimen without the cytokine, our groups are currently randomizing the original regimen, without IFN, against standard modulated bolus FUra.

Original languageEnglish
Pages (from-to)341-346
Number of pages6
JournalBritish Journal of Cancer
Volume77
Issue number2
Publication statusPublished - 1998

Fingerprint

Fluorouracil
Colorectal Neoplasms
Appointments and Schedules
Methotrexate
Leucovorin
Cytokines
Treatment Failure
Survival
Therapeutics

Keywords

  • 5-fluorouracil
  • Advanced colorectal cancer
  • Biochemical modulation
  • Natural-β-interferon
  • Schedule of administration

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer : A multicentric phase II study. / Aschele, C.; Guglielmi, A.; Frassineti, G. L.; Milandri, C.; Amadori, D.; Labianca, R.; Vinci, M.; Tixi, L.; Caroti, C.; Ciferri, E.; Verdi, E.; Rosso, R.; Sobrero, A.

In: British Journal of Cancer, Vol. 77, No. 2, 1998, p. 341-346.

Research output: Contribution to journalArticle

Aschele, C, Guglielmi, A, Frassineti, GL, Milandri, C, Amadori, D, Labianca, R, Vinci, M, Tixi, L, Caroti, C, Ciferri, E, Verdi, E, Rosso, R & Sobrero, A 1998, 'Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: A multicentric phase II study', British Journal of Cancer, vol. 77, no. 2, pp. 341-346.
Aschele, C. ; Guglielmi, A. ; Frassineti, G. L. ; Milandri, C. ; Amadori, D. ; Labianca, R. ; Vinci, M. ; Tixi, L. ; Caroti, C. ; Ciferri, E. ; Verdi, E. ; Rosso, R. ; Sobrero, A. / Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer : A multicentric phase II study. In: British Journal of Cancer. 1998 ; Vol. 77, No. 2. pp. 341-346.
@article{25da521fd5fc46e9a1b33d1dfb40c96e,
title = "Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: A multicentric phase II study",
abstract = "We have recently reported high clinical activity against advanced colorectal cancer of a regimen-alternating bolus FUra, modulated by methotrexate (MTX), and continuous infusion FUra, modulated by 6-s-leucovorin (6-s-LV). Considering the low toxicity of the bolus part of this regimen and our recent in vitro finding of a strong synergism between bolus FUra and natural-β-IFN (n-β-IFN), this cytokine was incorporated in the bolus part of our treatment programme. Fifty-six patients with untreated, advanced, measurable colorectal cancer were treated with two biweekly cycles of FUra bolus (600 mg m-2), modulated by MTX (24 h earlier, 200 mg m-2), and n-β-IFN (3 x 106 IU i.m. every 12 h, starting at the time of FUra administration for four doses), alternating with a 3-week continuous infusion of FUra (200 mg m-2 daily), modulated by 6-s-LV (20 mg m-2 weekly bolus). After a 1-week rest, the whole cycle (8 weeks) was repeated if indicated. A total of 5 complete and 17 partial responses were obtained (response rate, 41{\%}; 95{\%} confidence limits, 28-55{\%}) in 54 assessable patients. After a median follow-up time of 36 months, five patients are still alive. Overall, the median time to treatment failure was 6.4 months. The median duration of survival was 15.0 months. There was one treatment-related death after a course of MTX → bolus FUra/n-β-IFN and grade III-IV toxicity occurred in 18{\%} of the patients. As the addition of n-β-IFN results in high toxicity, whereas the efficacy seems to be similar to that of the same regimen without the cytokine, our groups are currently randomizing the original regimen, without IFN, against standard modulated bolus FUra.",
keywords = "5-fluorouracil, Advanced colorectal cancer, Biochemical modulation, Natural-β-interferon, Schedule of administration",
author = "C. Aschele and A. Guglielmi and Frassineti, {G. L.} and C. Milandri and D. Amadori and R. Labianca and M. Vinci and L. Tixi and C. Caroti and E. Ciferri and E. Verdi and R. Rosso and A. Sobrero",
year = "1998",
language = "English",
volume = "77",
pages = "341--346",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer

T2 - A multicentric phase II study

AU - Aschele, C.

AU - Guglielmi, A.

AU - Frassineti, G. L.

AU - Milandri, C.

AU - Amadori, D.

AU - Labianca, R.

AU - Vinci, M.

AU - Tixi, L.

AU - Caroti, C.

AU - Ciferri, E.

AU - Verdi, E.

AU - Rosso, R.

AU - Sobrero, A.

PY - 1998

Y1 - 1998

N2 - We have recently reported high clinical activity against advanced colorectal cancer of a regimen-alternating bolus FUra, modulated by methotrexate (MTX), and continuous infusion FUra, modulated by 6-s-leucovorin (6-s-LV). Considering the low toxicity of the bolus part of this regimen and our recent in vitro finding of a strong synergism between bolus FUra and natural-β-IFN (n-β-IFN), this cytokine was incorporated in the bolus part of our treatment programme. Fifty-six patients with untreated, advanced, measurable colorectal cancer were treated with two biweekly cycles of FUra bolus (600 mg m-2), modulated by MTX (24 h earlier, 200 mg m-2), and n-β-IFN (3 x 106 IU i.m. every 12 h, starting at the time of FUra administration for four doses), alternating with a 3-week continuous infusion of FUra (200 mg m-2 daily), modulated by 6-s-LV (20 mg m-2 weekly bolus). After a 1-week rest, the whole cycle (8 weeks) was repeated if indicated. A total of 5 complete and 17 partial responses were obtained (response rate, 41%; 95% confidence limits, 28-55%) in 54 assessable patients. After a median follow-up time of 36 months, five patients are still alive. Overall, the median time to treatment failure was 6.4 months. The median duration of survival was 15.0 months. There was one treatment-related death after a course of MTX → bolus FUra/n-β-IFN and grade III-IV toxicity occurred in 18% of the patients. As the addition of n-β-IFN results in high toxicity, whereas the efficacy seems to be similar to that of the same regimen without the cytokine, our groups are currently randomizing the original regimen, without IFN, against standard modulated bolus FUra.

AB - We have recently reported high clinical activity against advanced colorectal cancer of a regimen-alternating bolus FUra, modulated by methotrexate (MTX), and continuous infusion FUra, modulated by 6-s-leucovorin (6-s-LV). Considering the low toxicity of the bolus part of this regimen and our recent in vitro finding of a strong synergism between bolus FUra and natural-β-IFN (n-β-IFN), this cytokine was incorporated in the bolus part of our treatment programme. Fifty-six patients with untreated, advanced, measurable colorectal cancer were treated with two biweekly cycles of FUra bolus (600 mg m-2), modulated by MTX (24 h earlier, 200 mg m-2), and n-β-IFN (3 x 106 IU i.m. every 12 h, starting at the time of FUra administration for four doses), alternating with a 3-week continuous infusion of FUra (200 mg m-2 daily), modulated by 6-s-LV (20 mg m-2 weekly bolus). After a 1-week rest, the whole cycle (8 weeks) was repeated if indicated. A total of 5 complete and 17 partial responses were obtained (response rate, 41%; 95% confidence limits, 28-55%) in 54 assessable patients. After a median follow-up time of 36 months, five patients are still alive. Overall, the median time to treatment failure was 6.4 months. The median duration of survival was 15.0 months. There was one treatment-related death after a course of MTX → bolus FUra/n-β-IFN and grade III-IV toxicity occurred in 18% of the patients. As the addition of n-β-IFN results in high toxicity, whereas the efficacy seems to be similar to that of the same regimen without the cytokine, our groups are currently randomizing the original regimen, without IFN, against standard modulated bolus FUra.

KW - 5-fluorouracil

KW - Advanced colorectal cancer

KW - Biochemical modulation

KW - Natural-β-interferon

KW - Schedule of administration

UR - http://www.scopus.com/inward/record.url?scp=14444267315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14444267315&partnerID=8YFLogxK

M3 - Article

C2 - 9461008

AN - SCOPUS:14444267315

VL - 77

SP - 341

EP - 346

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -